



#### CME Session 4

Oncology and Theranostics Committee

Sunday, September 10, 16:45-18:15

#### Session Title

**Update in Multiple Myeloma**

#### Chairpersons

**Cristina Nanni** (Bologna, Italy)

**Clement Bailly** (Nantes, France)

#### Programme

16:45 - 17:05 **Cristina Nanni** (Bologna, Italy): Genomic vs FDG Patterns

17:05 - 17:25 **Andreas Buck** (Wurzburg, Germany): Radioligand Therapy

17:25 - 17:50 **Charles Mesguich** (Bordeaux, France): FDG PET/CT, DWI or Both?

17:50 - 18:15 **Francoise Krabere-Bodere** (Nantes, France): ImmunoPET

#### Educational Objectives

1. To learn about the role of PET imaging over genomic tests
2. To have a new insight into the emerging field of radioligand therapy
3. To have a new insight into WB-MRI in MM in comparison or associated to FDG PET/CT
4. To understand the potential role of new tracers for immunoPET in MM

#### Summary

FDG PET/CT is recommended by the International Myeloma Working Group (IMWG) as an useful procedure to stratify patients with different outcomes at different time points. It is becoming clearer and clearer that its strength relies especially on therapy assessment: FDG PET/CT is, in fact, able to recognize areas of minimal residual disease, integrating the clinical definition of complete responders. However, the contribution of FDG PET/CT in the workup of MM patients has to face new diagnostic techniques such as the genomic testing on the bone marrow and peripheral blood as well as whole body DWI and new tracers for immunoPET, each of those showing potential advantages and disadvantages in the clinical practice. Furthermore, the new growing field of theragnostic will be discussed in the light of possible future applications in this field.

#### Key Words

PET/CT, Multiple Myeloma, WB-MRI, ImmunoPET, Theragnostic